October 19, 2017
Joshua Brody, MD
The FDA approved axicabtagene ciloleucel as the first chimeric antigen receptor T-cell therapy to treat adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Axicabtagene ciloleucel (Yescarta; Kite, Gilead) is the second chimeric antigen receptor (CAR) T-cell therapy approved by the FDA — following the approval of tisagenlecleucel T-suspension (Kymriah, Novartis) for the treatment of children and young adults with B-cell acute lymphoblastic leukemia — and the first therapy of this type approved for some non-Hodgkin lymphomas.
October 17, 2017
Oncology leaders who participated in an American Association for Cancer Research webinar this afternoon highlighted several advances in cancer research and emphasized…
October 13, 2017
NIH launched the Partnership for Accelerating Cancer Therapies, a 5-year public-private research collaboration. The $215 million effort is part of the national cancer…
October 11, 2017
HemOnc Today is pleased to announce plans for a 3-day CME meeting designed to offer expert perspectives and practical insights into the use of immunotherapy and…